Trevena Inc (TRVN)
0.7438
-0.02 -2.77%
NASDAQ
Dec 13, 20:00
Delayed 2m
USD
Trevena Sell Recommendations
View 4,000+ financial data types
Browse...
View Full Chart
Sell Recommendations Chart
Historical Sell Recommendations Data
View and export this data going back to 2014.
Start your Free Trial
Export Data
Date Range:
Data for this Date Range | |
---|---|
Nov. 5, 2019 | Upgrade |
Nov. 4, 2019 | Upgrade |
Sept. 3, 2019 | Upgrade |
Aug. 29, 2019 | Upgrade |
Aug. 8, 2019 | Upgrade |
Aug. 7, 2019 | Upgrade |
June 24, 2019 | Upgrade |
May 31, 2019 | Upgrade |
May 13, 2019 | Upgrade |
March 14, 2019 | Upgrade |
March 13, 2019 | Upgrade |
Feb. 5, 2019 | Upgrade |
Jan. 28, 2019 | Upgrade |
Dec. 31, 2018 | Upgrade |
Nov. 9, 2018 | Upgrade |
Nov. 8, 2018 | Upgrade |
Nov. 5, 2018 | Upgrade |
Oct. 26, 2018 | Upgrade |
Oct. 12, 2018 | Upgrade |
Oct. 10, 2018 | Upgrade |
Oct. 4, 2018 | Upgrade |
Sept. 14, 2018 | Upgrade |
Sept. 13, 2018 | Upgrade |
Sept. 10, 2018 | Upgrade |
Sept. 4, 2018 | Upgrade |
Aug. 31, 2018 | Upgrade |
Aug. 13, 2018 | Upgrade |
Aug. 6, 2018 | Upgrade |
Aug. 3, 2018 | Upgrade |
Aug. 1, 2018 | Upgrade |
July 6, 2018 | Upgrade |
June 29, 2018 | Upgrade |
June 20, 2018 | Upgrade |
June 1, 2018 | Upgrade |
May 7, 2018 | Upgrade |
May 4, 2018 | Upgrade |
May 3, 2018 | Upgrade |
May 1, 2018 | Upgrade |
April 27, 2018 | Upgrade |
April 2, 2018 | Upgrade |
March 21, 2018 | Upgrade |
March 12, 2018 | Upgrade |
March 8, 2018 | Upgrade |
March 7, 2018 | Upgrade |
March 1, 2018 | Upgrade |
Feb. 1, 2018 | Upgrade |
Jan. 3, 2018 | Upgrade |
Jan. 2, 2018 | Upgrade |
Dec. 21, 2017 | Upgrade |
Dec. 1, 2017 | Upgrade |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Sell Recommendations for TRVN
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Sell Recommendations Benchmarks
Benchmarks | |
---|---|
EyePoint Pharmaceuticals Inc | Upgrade |
Heron Therapeutics Inc | Upgrade |
Mersana Therapeutics Inc | Upgrade |
Sell Recommendations Range, Past 5 Years
Minimum | Upgrade | Dec 19 2014 |
Maximum | Upgrade | Dec 19 2014 |
Average | Upgrade |
News
Trevena's Early-Stage Trials Show No Dose Adjustments Needed in Oliceridine in Renal Disease - Stock Up 2%
MT Newswires 11/20 13:08 ET
MT Newswires 11/20 13:08 ET
Trevena reports results from special population studies for oliceridine
SA Breaking News 11/20 08:37 ET
SA Breaking News 11/20 08:37 ET
Trevena Announces Publication of Results from Special Population Studies for Oliceridine
Globe Newswire 11/20 07:00 ET
Globe Newswire 11/20 07:00 ET
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
Globe Newswire 11/04 07:00 ET
Globe Newswire 11/04 07:00 ET